Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss

Exonate is a privately held, early stage, biotech, company spun out of the University of Nottingham
that is focused on Vascular Endothelial Growth Factor (VEGF). The Company has grown
significantly in the last year as it welcomes investment and input from an increasing Global
market.

It aspires to successfully deliver medicines in areas of unmet need, by targeting diseases through
regulation of VEGF isoforms/variants that are both protective and disease promoting. Exonate’s
lead program is focused on wet Age-Related Macular Degeneration, (wet AMD), which is the
leading cause of vision loss in people aged 60 and older. The Company is founded on scientific
excellence with strong links to Prof. David Bates and his lab at Nottingham University
specialising in the biology and biochemical pathways of VEGF splice variants. In addition Exonate
has formed academic collaborations with the university of New South Wales (Australia) and
Professor Jonathan Morris.

Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through
selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These
inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet
AMD.

Exonate is led by an experienced, international management team that has worked together
previously, successfully raising capital for start-ups and early stage companies over many years.
Exonate’s management has cross-disciplinary experience in medicine, finance, drug development
and the pharmaceutical and biotech industries. CEO Catherine Beech, has over 25 years
biotech/pharma experience including 12 years in big pharma leading development programs in
cardiovascular, Parkinson’s disease and HIV.